January 7, 2021
Kala Pharmaceuticals has announced the launch of Eysuvis™ (loteprednol etabonate ophthalmic suspension), which received U.S. FDA approval on October 26, 2020. Eysuvis is indicated to provide short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (DED). The product is the first ocular steroid to be FDA approved specifically for DED.
When the body fails to produce enough tears or to produce good quality tears, this leads to a lack of lubrication on the eye’s surface which can in turn cause inflammation and injury of the eye. Patients may feel a stinging or scratchiness in the eye, perhaps accompanied by the sensation of a foreign body being trapped in the eye. Patients may also experience light sensitivity, difficulty driving at night, blurred vision, and eye fatigue. They may also be more prone to eye infections. Corticosteroids like Eysuvis can help reduce inflammation, which helps to ease symptoms of DED.
Eysuvis uses AMPPLIFY® mucus-penetrating particle drug delivery technology to enhance the penetration of the active pharmaceutical ingredient into the tissue on the eye’s surface. In clinical trials, Eysuvis demonstrated a rapid effect, helping to quickly relieve the symptoms of DED. Recommended dosing is one to two drops in the affected eye(s) four times daily for no more than two weeks. The Eysuvis dropper bottle should be shaken for 2-3 seconds before use.
The wholesale acquisition cost (WAC) for Eysuvis is $465 per bottle.